Compare AEF & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AEF | VNDA |
|---|---|---|
| Founded | 1989 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 315.9M | 474.0M |
| IPO Year | N/A | 2005 |
| Metric | AEF | VNDA |
|---|---|---|
| Price | $7.38 | $6.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.90 |
| AVG Volume (30 Days) | 183.0K | ★ 1.6M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 7.13% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | N/A | ★ $216,105,000.00 |
| Revenue This Year | N/A | $21.35 |
| Revenue Next Year | N/A | $37.40 |
| P/E Ratio | $12.95 | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $4.43 | $3.81 |
| 52 Week High | $8.93 | $9.91 |
| Indicator | AEF | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 45.19 | 42.47 |
| Support Level | $6.10 | $4.39 |
| Resistance Level | $8.09 | $8.29 |
| Average True Range (ATR) | 0.21 | 0.44 |
| MACD | -0.00 | -0.14 |
| Stochastic Oscillator | 51.02 | 16.93 |
ABERDEEN EMERGING MARKETS EQUITY INCOME FUND, INC. is a closed-end investment company. The Fund's investment objective is to seek to provide both current income and long-term capital appreciation. The Fund invests in a range of sectors, including financials, consumer staples, utilities, consumer discretionary, materials, energy, information technology, private equity, communication services, healthcare, real estate, and industrials.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.